(2S,3S)-4-cyclopropyl-3-{(3R,5R)-3-[2-fluoro-4-(methylsulfonyl)phenyl]-1,2,4-oxadiazolidin-5-yl}-1-[(3S)-3-fluoropyrrolidin-1-yl]-1-oxobutan-2-amine

This compound is a synthetic small molecule inhibitor of dipeptidyl peptidase 4 (DPP-IV), also known as CD26. DPP-IV is an enzyme involved in the degradation of incretin hormones such as GLP‑1 and GIP. Inhibition of DPP-IV increases levels of these hormones and can enhance insulin secretion and lower blood glucose levels. The compound has been studied experimentally for its potential use in metabolic disorders such as type 2 diabetes mellitus but does not have an approved indication or brand name. It is referenced in DrugBank under the accession number DB06993 and has been structurally characterized in complex with human DPP-IV[6][8][1].

Other names

(2S,3S)-2-amino-4-cyclopropyl-3-{(3R,5R)-3-[2-fluoro-4-(methylsulfonyl)phenyl]-1,2,4-oxadiazolidin-5-y}-1-{(3S)-3-fluoropyrrolidin-l-y}-l -oxobutan - 2 - amine(2S, 3S ) - 4-cyclopropyl - 3-{( 35 ,55 ) - 35 [24 fluoro44(methylsulfon yl) phen yl]12 ,44 oxadiazolidin55 yl}11 [(35 )34 fluoropyrrolidin11 y]11 oxobutan22 amine[6][2]